|
Initial dosing strategy of thromboprophylaxis
|
No. of patients
|
Events/person-days
|
IR per 1.000 person-days (95% CI)
|
HR (95% CI) of death ≤ 28 days
|
|---|
|
Univariable model
|
Multivariable modela
|
Multivariable imputed modelb
|
|---|
|
High dosec
|
37
|
5/923
|
5.4 (2.3–13.0)
|
0.31 (0.12–0.82)
|
0.33 (0.13–0.87)
|
0.30 (0.11–0.81)
|
|
Medium dosed
|
48
|
12/1182
|
10.2 (5.8–17.9)
|
0.59 (0.30–1.16)
|
0.88 (0.43–1.83)
|
0.87 (0.42–1.82)
|
|
Low dosee
|
67
|
26/1453
|
17.9 (12.2–26.3)
|
1.00 (Ref.)
|
1.00 (Ref.)
|
1.00 (Ref.)
|
- Risk of death during the first 28 days among 152 patients admitted to the intensive care unit due to COVID-19 at Södersjukhuset, Stockholm, March 6 to April 30, 2020, by initial dosing strategy with tinzaparin/dalteparin as thromboprophylaxis
- CI, confidence interval; IR, Incidence Rate; HR, Hazard Ratio
- aAdjusted for sex, age (continuously), body mass index (</≥ 30 kg/m2 and missing [n = 6]), invasive mechanical ventilation (yes/no), and Simplified Acute Physiology Score III (continuously)
- bAdjusted like the multivariable model but with body mass index imputed due to missing values (n = 6), and flexibly modeled with restricted cubic splines at three knots over the percentile (10th, 50th, and 90th) distribution of body mass index in the population
- cTinzaparin, ≥ 175 IU/kg of body weight per daily, or dalteparin, ≥ 200 IU/kg of body weight daily
- dTinzaparin, > 4500 IU daily to < 175 IU/kg of body weight daily, or dalteparin, > 5000 IU daily to < 200 IU/kg of body weight daily
- eTinzaparin, 2500–4500 IU daily, or dalteparin, 2500–5000 IU daily
